Fineline Cube

Follow:
14422 Articles
PADCEV Yields 60 % EFS Reduction in MIBC – Astellas‑Pfizer EV‑303 Study
CompanyDrug

PADCEV Yields 60 % EFS Reduction in MIBC – Astellas‑Pfizer EV‑303 Study

AbbVie’s SELECT‑SWITCH Study Confirms Upadacitinib Outperforms Adalimumab in RA
CompanyDrug

AbbVie’s SELECT‑SWITCH Study Confirms Upadacitinib Outperforms Adalimumab in RA

Harbour BioMed Reports Phase II Success of Porustobart in MSS mCRC
CompanyDrug

Harbour BioMed Reports Phase II Success of Porustobart in MSS mCRC

VBP 11th Finalizes 389 Participants, 3.7 Billion Doses Set for Centralized Procurement
Policy / Regulatory

VBP 11th Finalizes 389 Participants, 3.7 Billion Doses Set for Centralized Procurement

Roche Reports 7 % YoY Revenue Growth Through Q3 2025, Raises Full‑Year Guidance
Company

Roche Reports 7 % YoY Revenue Growth Through Q3 2025, Raises Full‑Year Guidance

Novo Nordisk Board Shake‑Up: Chairman Helge Lund and Six Members Step Down After Disagreement With Foundation
Company

Novo Nordisk Board Shake‑Up: Chairman Helge Lund and Six Members Step Down After Disagreement With Foundation

Innovent and Takeda Forge $11.4 B Partnership on IBI363, IBI343 & IBI3001 ADC Therapies
CompanyDeals

Innovent and Takeda Forge $11.4 B Partnership on IBI363, IBI343 & IBI3001 ADC Therapies

Galapagos Announces Exit from Cell‑Therapy Business After Strategic Review
Company

Galapagos Announces Exit from Cell‑Therapy Business After Strategic Review

GFH375 Enters Phase Ib/II at Peking University: GenFleet Targets KRAS G12D
CompanyDrug

GFH375 Enters Phase Ib/II at Peking University: GenFleet Targets KRAS G12D

Rani Therapeutics and Chugai Forge $1.085 Billion Collaboration Deal for Innovative Oral Therapeutic
CompanyDeals

Rani Therapeutics and Chugai Forge $1.085 Billion Collaboration Deal for Innovative Oral Therapeutic

BIREOCCILIB OUTPERFORMS TRADITIONAL CDK4/6 IN BRIGHT‑3: Xuanzhu Biopharma Announces Interim Phase III Results at ESMO 2025
CompanyDrug

BIREOCCILIB OUTPERFORMS TRADITIONAL CDK4/6 IN BRIGHT‑3: Xuanzhu Biopharma Announces Interim Phase III Results at ESMO 2025

Sichuan Biokin Secures NMPA Approval for BL‑M24D1 ADC, Targeting Relapsed Hematologic and Solid Tumors
CompanyDrug

Sichuan Biokin Secures NMPA Approval for BL‑M24D1 ADC, Targeting Relapsed Hematologic and Solid Tumors